Literature DB >> 29536537

Effect of verbascoside on apoptosis and metastasis in human oral squamous cell carcinoma.

Yaqin Zhang1, Yi Yuan2,3, Heming Wu3, Zhuoying Xie4, Yunong Wu3, Xiaomeng Song3, Jingjing Wang1, Wei Shu5, Junyong Xu3, Bin Liu6, Linzhong Wan3, Yanan Yan3, Xu Ding3, Xinghui Shi3, Yongchu Pan3, Xiaokang Li2,7, Jianrong Yang3, Xiaohui Zhao8, Lin Wang2,3.   

Abstract

Despite significant advances in therapy, the 5-year survival rates for patients with advanced stage oral cancers still remains poor as an appropriate treatment has not been found yet, due to side effects of chemo/radiotherapy. Verbascoside (VB), a major bioactive constituent of the Tsoong herb, displays pharmacological properties by exhibiting anti-oxidative, anti-inflammatory and anti-cancer activities. However, the underlining function and mechanism of VB in human oral squamous cell carcinoma (OSCC) remains unclear. In this study, we show that VB significantly decreased the viability and metastasis of HN4 and HN6 tumor cells, while promoting apoptosis. A xenograft OSCC mouse model further showed that intraperitoneal injection of VB strongly inhibited growth and lung metastasis of implanted tumor cells. Immunoblot analysis confirmed that VB effectively suppressed nuclear factor (NF)-κB activation and downstream Bcl-2/Bcl-XL expression, resulting in increased OSCC cell apoptosis. In addition, VB suppressed mRNA and protein expression of matrix metalloproteinase-9 via suppression of NF-κB activation, thereby inhibiting tumor cell metastasis. Inspiringly, compared to cisplatin-treated group, VB is a biocompatible agent without signficant side effects in vivo. Collectively, our results demonstrate that VB effectively inhibits OSCC tumor cell growth and metastasis via suppression of IκB kinase complex (IKK)/NF-κB-related signaling activation, suggesting that VB has potential use as a potent anticancer agent in OSCC therapeutic strategies.
© 2018 UICC.

Entities:  

Keywords:  apoptosis; metastasis; nuclear factor-κB; oral squamous cell carcinoma; verbascoside

Mesh:

Substances:

Year:  2018        PMID: 29536537     DOI: 10.1002/ijc.31378

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  The pharmacokinetic property and pharmacological activity of acteoside: A review.

Authors:  Yaosheng Xiao; Qun Ren; Longhuo Wu
Journal:  Biomed Pharmacother       Date:  2022-06-17       Impact factor: 7.419

2.  The Anti-Tumor Efficacy of Verbascoside on Ovarian Cancer via Facilitating CCN1-AKT/NF-κB Pathway-Mediated M1 Macrophage Polarization.

Authors:  Yu Ren; Jinying He; Wenhua Zhao; Yuzhen Ma
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  Formulation of a Phenol-Rich Extract from Unripe Olives (Olea europaea L.) in Microemulsion to Improve Its Solubility and Intestinal Permeability.

Authors:  Lorenzo Cecchi; Vieri Piazzini; Mario D'Ambrosio; Cristina Luceri; Federica Rocco; Marzia Innocenti; Giulia Vanti; Nadia Mulinacci; Maria Camilla Bergonzi
Journal:  Molecules       Date:  2020-07-13       Impact factor: 4.411

4.  Tomato and Olive Bioactive Compounds: A Natural Shield against the Cellular Effects Induced by β-Hexachlorocyclohexane-Activated Signaling Pathways.

Authors:  Elisabetta Rubini; Marco Minacori; Giuliano Paglia; Alberto Macone; Silvia Chichiarelli; Fabio Altieri; Margherita Eufemi
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

5.  The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line.

Authors:  Atena Daneshforouz; Samad Nazemi; Omid Gholami; Marzieh Kafami; Bahareh Amin
Journal:  BMC Pharmacol Toxicol       Date:  2021-11-29       Impact factor: 2.483

Review 6.  The role of key gut microbial metabolites in the development and treatment of cancer.

Authors:  Kayla Jaye; Chun Guang Li; Dennis Chang; Deep Jyoti Bhuyan
Journal:  Gut Microbes       Date:  2022 Jan-Dec

7.  Exploring the Mechanism of Scutellaria baicalensis Georgi Efficacy against Oral Squamous Cell Carcinoma Based on Network Pharmacology and Molecular Docking Analysis.

Authors:  Fanfan Hou; Yang Liu; YaHsin Cheng; Ni Zhang; Wenpeng Yan; Fang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

8.  Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.

Authors:  Di Ma; Juan Wang; Lu Liu; Meiqi Chen; Zhiyong Wang
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.